Zimmer Biomet (ZBH) Stock
Global maker of joint replacement and spinal implants. Here's the price, business snapshot, and what's worth knowing about Zimmer Biomet in June 2026.
Zimmer Biomet Holdings, Inc. (ZBH) is a global medical‑device company specialising in musculoskeletal healthcare — primarily joint replacement, spinal and dental solutions. With a market capitalisation around $20.3bn, it serves hospitals, surgeons and clinics through product sales, aftermarket services and implants. Key growth drivers include ageing populations, increasing demand for elective orthopaedic procedures and geographic expansion in emerging markets. Investors should watch procedure volumes, product mix, pricing pressure, merger and acquisition activity and reimbursement trends — these affect revenue and margins. The business is also exposed to regulatory, litigation and supply‑chain risks that can affect performance. Financially, margins can improve with scale and operational efficiency, but outcomes vary by cycle and region. This summary is educational and not personalised investment advice; shares can fall as well as rise. Consider your objectives and risk tolerance or consult a regulated adviser before acting.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Zimmer Biomet's stock, expecting it to rise towards the target price.
Financial Health
Zimmer Biomet is performing well with strong revenue, profit margins, and cash flow generation.
Dividend
Zimmer Biomet's dividend yield of 1.12% is relatively low, making it less appealing for dividend-focused investors. If you invested $1000 you would be paid $9.60 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring ZBH
MedTech Stocks: Brazil Market Risks & Opportunities
Brazil's growing demand for advanced healthcare presents an opportunity to modernize its medical infrastructure and improve patient outcomes. This basket offers exposure to the leading US and European companies supplying Brazil with robotic surgery systems, AI diagnostics, and innovative medical devices.
Published: 21 October 2025
Explore BasketHealthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: 22 September 2025
Explore BasketWhy You’ll Want to Watch This Stock
Aging population demand
An older population supports long‑term demand for joint replacements and related care, though procedure cycles and reimbursement can cause variability.
Global market exposure
Broad geographic presence can fuel growth as emerging markets adopt advanced care, but it also brings currency, regulatory and supply‑chain risks.
R&D and margins
Innovation and product mix can lift margins over time, yet investment cycles and competitive pricing pressure mean outcomes are uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
